3-boronobenzenesulfonamide
Product Information
Molecular Formula
C6H8BNO4S
Molecular Weight
201.01
Description
3-boronobenzenesulfonamide can specifically target tumor cells and block their tendency to proliferate while orchestrating their intracellular self-destruction.
Synonyms
3-(Aminosulphonyl)benzeneboronic acid; (3-sulfamoylphenyl)boronic acid; 3-sulfamoylphenylboronic acid; Boronic acid B-3-(aminosulfony)pheny; Boronic acid, [3-(aminosulfonyl)phenyl]-; (3-Aminosulphonyl)benzeneboronic acid; SCHEMBL585145; 3-Sulfamoyl-benzeneboronic acid; 3-(Aminosulphonyl)benzeneboronicacid; [3-(aminosulfonyl)phenyl]boronic acid; 3-boronobenzenesulfonamide; 3-SULPHAMOYLBENZENEBORONIC ACID; 3-sulfamoylphenylboronic acid; 3-Boronobenzenesulphonamide
IUPAC Name
(3-sulfamoylphenyl)boronic acid
SMILES
B(C1=CC(=CC=C1)S(=O)(=O)N)(O)O
InChI
InChI=1S/C6H8BNO4S/c8-13(11,12)6-3-1-2-5(4-6)7(9)10/h1-4,9-10H,(H2,8,11,12)
InChI Key
PMNJSWJJYWZLHU-UHFFFAOYSA-N
Flash Point
Not applicable
Computed Properties
Hydrogen Bond Donor Count
3
Hydrogen Bond Acceptor Count
5
Rotatable Bond Count
2
Exact Mass
201.0267091 g/mol
Monoisotopic Mass
201.0267091 g/mol
Topological Polar Surface Area
109Ų
Heavy Atom Count
13
Formal Charge
0
Complexity
260
Isotope Atom Count
0
Defined Atom Stereocenter Count
0
Undefined Atom Stereocenter Count
0
Defined Bond Stereocenter Count
0
Undefined Bond Stereocenter Count
0
Covalently-Bonded Unit Count
1
Compound Is Canonicalized
Yes
Patents
| Publication Number | Title | Priority Date |
|---|---|---|
| EP-3878891-A1 | Dynamic covalent hydrogels, precursors thereof and uses thereof | 2020-03-10 |
| WO-2021180795-A1 | Dynamic covalent hydrogels, precursors thereof and uses thereof | 2020-03-10 |
| WO-2020242245-A1 | Phthalazinone compounds and use thereof | 2019-05-29 |
| CN-113840820-A | Phthalazinone compounds and uses thereof | 2019-05-29 |
| KR-20210137216-A | Phthalazinone compounds and uses thereof | 2019-05-29 |
| US-2020003773-A1 | Optical detection of biological components | 2018-04-05 |
| WO-2019173761-A1 | C-abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | 2018-03-09 |
| US-2021101872-A1 | C-abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | 2018-03-09 |
| AU-2016335043-A1 | Compounds for treatment of cancer and epigenetics | 2015-10-09 |
| CA-3001452-A1 | Compounds for treatment of cancer and epigenetics | 2015-10-09 |
